Siegfried Holding AG has completed its previously announced acquisition of the contract drug-manufacturing businesses Noramco, Extractas Biosciences and Purisys from affiliates of private-equity firm SK Capital Partners, expanding the Swiss group’s footprint in pharmaceutical contract development and manufacturing. The acquisition is part of Siegfried’s EVOLVE+ strategy to expand the company’s presence and capacity in the U.S., the world’s largest pharmaceutical market. The deal adds capacity...